Paul Saladino· MD
my suspicion is that she is headed for Ozempic instead.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
my suspicion is that she is headed for Ozempic instead.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
ozempic or semi-glutide ugovi is a class of drug called a glp-1 Agonist and it is uh really right now the Prototype weight loss drug